MacroGenics | MGNX - Operating Profit


MacroGenics reported $18.64M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Genmab DKK 360M 172M Jun/2025
Geron USD -10.79M 3.1M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
MacroGenics USD 18.64M 55.4M Sep/2025
Merck USD 6.24B 318M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Xencor USD -47.52M 14.35M Sep/2025